Pharmaceutical aspects of paclitaxel

International Journal of Pharmaceutics

Volumn 172, Issue 1-2, 1998, Pages 1-15

  Panchagnula, Ramesh ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Drug delivery; Paclitaxel; Pharmaceutical aspects

Indexed keywords

ALCOHOL; BETA CYCLODEXTRIN DERIVATIVE; CISPLATIN; CORTICOSTEROID; CREMOPHOR; CYCLOPHOSPHAMIDE; DOCETAXEL; LIPOSOME; MACROGOL; MICROSPHERE; PACLITAXEL; POLYMER; POLYVINYLCHLORIDE; VERAPAMIL;

ANTINEOPLASTIC ACTIVITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INFORMATION; DRUG MECHANISM; GASTROINTESTINAL TOXICITY; HUMAN; LIVER TOXICITY; MICELLE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

EID: 0032531883     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(98)00188-4     Document Type: Review

References (114)

1. Allwood M., Martin H. The extraction of diethylhexylphthalate (DEHP) from polyvinyl chloride components of intravenous infusion containers and administration sets by paclitaxel injection. Int. J. Pharm. 127:1996;65-71.
2. Anon. Paclitaxel (Taxol) for ovarian cancer. Med. Lett. Drugs Ther. 35:1993;39-40.
3. Anon. Fighting cancer with yew. Manuf. Chem. 67:1996;35-37.
4. Balasubramanian S., Aldefer J.L., Straubinger R.M. Solvent- and concentration-dependent interactions of taxol (paclitaxel). J. Pharm. Sci. 83:1994;1470-1476.
5. Bartoli H., Boitard M., Fessi H., Beriel H., Devissagnet J.P., Picot F., Puisien F. In vitro and in vivo antitumoral activity of free and encapsulated taxol. J. Microencapsulation. 7:1990;191-197.
6. Berg S., Tolcher A., O'Shaughnessy J.A., Denicoff A.M., Noone M., Ognibene F.P., Cowan K.H., Balis F.M. Effect of R verapamil on the pharmacokinetics of paclitaxel in women with breast cancer. J. Clin. Oncol. 13:1995;2039-2042.
7. Blume E. Investigator seek to increase taxol supply. J. Natl. Cancer Inst. 81:1989;1122-1123.
8. Bundgaard H. Prodrugs as a means to improve the delivery of peptide drugs. Adv. Drug Deliv. Rev. 8:1992;1-38.
9. Burt H., Jackson J.K., Sarvjeet B.K., Liggins R.T., Oktaba A.M., Arsenault L.A., Hunter W.L. Controlled delivery of taxol from microspheres composed of blend of ethylene-vinyl acetate copolymer and poly(d,l-lactic acid). Cancer Lett. 88:1995;73-79.
10. Capri G., Tarenzi E., Fulfaro F., Gianni L. The role of taxanes in the treatment of breast cancer. Semin Oncol. 1:1996;68-75.
11. HER2 antibody for human cancer therapy. Proc. Natl. Acad. Sci. USA. 89:1992;4285-4289.
12. Chaudhary A., Rimoldi J.M., Kingston D.G.I. Modified taxol. 10. Preparation of 7-doxytaxol, a highly bioactive taxol derivative and interconversion of taxol and 7-epi-taxol. J. Org. Chem. 58:1993;3798-3799.
13. Chunekar, K., Pandey, G.S., 1990. Bhavaprakasa Nighantu of Sri Bhavamisra (Indian Materia Medica). Chaukhambha Bharati Academy, Varanasi.
14. Colin, M., Guenard, D., Guritte-Voegelein, F., 1990. Process for preparing derivatives of baccatin III and of 10-deacetyl baccatin III. US Patent 4924012.
15. Cowden J.C., Paterson I. Cancer drugs better than taxol? Nature. 387:1997;238-239.
16. Cserhati T., Hollo J. Interaction of taxol and other anticancer drugs with hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 108:1994;69-75.
17. Cserhati T., Forgacs E., Hollo J. Interaction of taxol and other anticancer drugs with alpha-cyclodextrin. J. Pharm. Biomed. Anal. 13:1995;541-553.
18. Dabur Pharmaceuticals, 1994. Intaxel, Administration Guide. Dabur Pharmaceuticals Ltd., New Delhi.
19. Deutsch H., Glinski J.A., Hernandz M., Haugwitsz X., Narayanan V.L., Suffness M., Zalkow L.H. Synthesis of congeners and prodrugs. 3. Water-soluble prodrugs of taxol with potent antitumor activity. J. Med. Chem. 32:1989;788-792.
20. Dordunoo S., Burt H.M. Solubility and stability of taxol: effects of buffers and cyclodextrins. Int. J. Pharm. 133:1996;191-201.
21. Dordunoo S., Jackson J.K., Arsenault L.A., Okataba A.M.C., Hunter W.L., Burt H.M. Taxol encapsulation in poly(E-caprolactone) microspheres. Cancer Chemother. Pharmacol. 36:1995;279-282.
22. Dordunoo S., Oktaba A.M.C., Hunter W., Min W., Cruz T., Burt H.M. Release of taxol from poly(ε-caprolactone) pastes: effect of water soluble additives. J. Control. Release. 44:1997;87-94.
23. Dosio F., Brusa P., Crosasso P., Arpicco S., Cattel L. Preparation and characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugates. J. Control. Release. 47:1997;293-304.
24. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs. 3:1992;175-210.
25. Duncan R., Spreafico F. Polymer conjugates, pharmacokinetics considerations for design and development. Clin. Pharmacokinet. 27:1994;290-306.
26. Ellis D., Zeldin E.L., Brodhagen M., Russin W.A., McCown B.H. Taxol production in nodule cultures of Taxus. J. Nat. Prod. 59:1996;246-250.
27. Fabre J., Locci-Tonelli D., Spiridonidis C.H. Docetaxel. Drugs Future. 20:1995;464-471.
28. Farber S., Diamond L.K., Mercer R.D., Sylvester R.F., Wolff V.A. Temporary remission in leukemia in children produced by folic anatagonist 4-aminopteroylglutamic acid (aminopterin). New Engl. J. Med. 238:1948;787-793.
29. Fields K., Partyka J.S., Perkins J.B., Elfenbein G.J. Optimization of high dose therapy for the treatment of patients with metastatic breast cancer. J. Oncol. Pharm. Pract. 2:1996;11-17.
30. Fiume L., Busi C., Mattioli A., Spinosa G. Targeting of antiviral drugs bound to protein carriers. CRC Crit. Rev. Ther. Drug Carrier Syst. 4:1988;265-284.
31. Gilman A., Philips F.S. The biological actions and therapeutic applications of the β-chlorethylamines and sulfides. Science. 103:1946;406-409.
32. Greenwald R., Pendri A., Bolikal D., Gilbert C.W. Highly water soluble taxol derivatives: 2′-polyethylene glycol esters as potential prodrugs. Bioorg. Med. Chem. Lett. 4:1994;2465-2470.
33. Greenwald R., Gilbert C.W., Pendri A., Conover C.D., Xia J., Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs - design and in vitro effectiveness. J. Med. Chem. 39:1996;424-431.
34. Gregory R., DeLisa A.F. Paclitaxel: a new antineoplastic agent for refractory ovarian cancer. Clin. Pharm. 12:1993;401-415.
35. Guenard D., Gueritte-Voegelein F., Poiter P. Taxol and Taxotere: discovery, chemistry and structure activity relationships. Account. Chem. Res. 26:1993;160-167.
36. Hartwell J., Schrecker A.W. Components of podophyllin (v) and podophyllotoxin. J. Am. Chem. Soc. 73:1951;2909-2916.
37. Hepperle M., George G.I. Taxol analogs. Drugs Future. 19:1994;573-584.
38. Holton R., Somoza C., Kim H.-B., Liang F., Biediger R.J., Boatman P.D. First total synthesis of taxol: 1. Functionalisation of B ring. J. Am. Chem. Soc. 116:1994;1597-1598.
39. Horwitz S. Mechanism of action of taxol. Trends Pharmacol. Sci. 13:1992;134-136.
40. Jachez B., Nordman R., Loor F. Restoration of taxol sensitivity of multi drug resistance cells by cyclosporine SDZ PSC 883 and cyclopeptide SDZ 280-446. J. Natl. Cancer Inst. 85:1993;478-483.
41. Jain R. Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res. 50:1990;814s-819s.
42. Jarho P., Urtti A., Jarvinen T. Hydroxypropyl-β-cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrugs. Pharm. Res. 12:1995;1371-1375.
43. Jenkins, P., 1996. Taxol branches out. Chem. Brit. November, 43-46.
44. Kingston D.G.I. The chemistry of Taxol. Pharmacol. Ther. 52:1991;1-34.
45. Kingston D.G.I. Taxol: the chemistry and structure activity relationsips of a novel anticancer agent. TIBTECH. 12:1994;222-227.
46. Kohler D., Goldspiel B.R. Paclitaxel (Taxol). Pharmacotherapy. 14:1994;3-34.
47. Kramer I., Heuser A. Paclitaxel pharmaceutical and pharmacological issues. Eur. Hosp. Pharm. 1:1995;37-41.
48. Kubo O., Tajika Y., Muragaki Y., Hiyama H., Takakurn H., Yoshida M., Kumakura M. Loxcal chemotherapy with slow releasing anticancer drug-polymers for maligant brain tumors. J. Control. Release. 32:1994;1-8.
49. Kuhn J. Pharmacology and pharmacokinetics of paclitaxel. Ann. Pharmacother. 28:1994;s15-s17.
50. Ma W., Park G.L., Gomez G.A., Nieder M.H., Shackleton C. New bioactive taxoids from cell cultures of Taxus baccata. J. Nat. Prod. 57:1994;116-122.
51. Mathew A., Mejillano M.R., Nath J.P., Himes R.H., Stella V.J. Synthesis and evaluation of some water soluble prodrugs and derivatives of taxol with antitumor activity. J. Med. Chem. 35:1992;145-151.
52. Mazzo D., Nguyen Huu J.J., Pagniez S., Denis P. Compatibility of docetaxel and paclitaxel in intravenous solutions with polyvinyl chloride infusion materials. Am. J. Health. Syst. Pharm. 54:1997;566-569.
53. Mead Johnson Oncology Products, 1997. Taxol (paclitaxel) for Injection Concentrate Prescribing Information. Bristol Myers Squibb, Princeton, NJ.
54. Merisko-Liversidge E., Sarpotdar P., Bruno J., Hajj S., Wei L., Peltier N., Rake J., Shaw J.M., Pugh S., Pollin L., Jones J., Corbett T., Cooper E., Liversidge G.G. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13:1996;272-278.
55. Nicolaou K., Riemer C., Kerr M.A., Rideout D., Wrasidlo W. Design, synthesis and biological activity of protaxol. Nature. 364:1993;464-466.
56. Nicolaou K., Dai W.M., Guy R.K. Chemistry and biology of taxol. Angew. Chem. Int. Ed. Engl. 33:1994;15-44.
57. Nicolaou K., Yang Z., Liu J.J., Ueno H., Biediger R.J., Guy R.K. Total synthesis of taxol. Nature. 367:1994;630-634.
58. Nicolaou K., Guy R.K., Nicolaou-Pitsinos E., Wrasidlo W. Water soluble prodrugs of taxol with self assembling properties. Angew. Chem. Int. Ed. Engl. 33:1994;1583-1587.
59. Nightingale S. Treatment IND/group C distribution for advanced metastatic ovarian cancer. J. Am. Med. Assoc. 268:1992;1390-1393.
60. Ohkwada K., Hatano T., Yamada K., Joh K., Tsukada Y., Matsuda M. Bovine serum albumin-doxorubicin conjugates overcome multidrug resistance in rat hepatoma. Cancer Res. 53:1993;4238-4242.
61. Ojima I., Park X., Sun C.M., Fenoglio I., Appendino G., Pera P., Bernacki R.H. Structure activity relationships of new taxoids derived from 14β-hydroxy-1-deacetylbaccatin III. J. Med. Chem. 37:1994;1408-1410.
62. Onyuksel H., Ramakrishanan S., Chai H.B., Pezzuto J.M. A mixed micellar formulation suitable for parenteral administration of taxol. Pharm. Res. 11:1994;206-212.
63. Panchagnula R., Dey C.S. Monoclonal antibodies in drug targeting. J. Clin. Pharm. Ther. 22:1997;7-19.
64. Parness J., Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91:1981;479-487.
65. Pfeifer R., Hale K.N. Precipitation of paclitaxel during infusion pump. Am. J. Hosp. Pharm. 50:1993;2518-2521.
66. Ramaswamy M., Zhang X., Burt H.M., Wasan K.M. Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers. J. Pharm. Sci. 86:1997;460-464.
67. Rao S., Krauss N.E., Heerding J.M. 3′-(p-Azidobenzamido)taxol photolabels the terminal 31-amino acids of beta-tubulin. J. Biol. Chem. 269:1994;3132-3134.
68. Rao K., Hanuman J.B., Alvarez C., Stoy M., Baxley R. New large scale process for taxol and related taxanes from Taxus brevifolia. Pharm. Res. 12:1995;1003-1010.
69. Ringel I., Horwitz S.B. Taxol converts to 7-epitaxol, a biological active isomer in cell culture medium. J. Pharmacol. Exp. Ther. 242:1987;692-698.
70. HER2 Fv-β-lactamase fusion protein for activation of cephlosporin doxorubicin prodrug. Cancer Res. 55:1995;63-70.
71. Rodrigues M., Carter P., Wirth C., Mullins S., Lee A., Blackburn B.K. Synthesis and β-lactamase-mediated activation of cephalosporin-taxol prodrug. Chem. Biol. 2:1995;223-227.
72. Rowinsky E., Donehower R.C. Taxol: twenty years later, the story unfolds. J. Natl. Cancer Inst. 83:1991;1778-1781.
73. Rowinsky E., Donehower R.C. Paclitaxel (Taxol). New Engl. J. Med. 332:1995;1004-1014.
74. Rowinsky E., Cazenava L.A., Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82:1990;1247-1259.
75. Rutherford C. Taxol administration. J. Intraven. Nurs. 17:1994;139-143.
76. Schiff P., Horwitz S.B. Taxol stabilizes microtubles in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA. 77:1980;1561-1565.
77. Schiff P., Fant J., Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature. 277:1979;665-667.
78. Seidman A. The emerging role of paclitaxel in breast cancer therapy. Clin. Cancer Res. 1:1995;247-256.
79. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations. Int. J. Pharm. 154:1997;123-140.
80. Sharma A., Straubinger R.M. Novel taxol formulations: preparation and characterization of taxol-containing liposomes. Pharm. Res. 11:1994;889-896.
81. Sharma A., Mayhew E., Straubinger R.M. Antitumor effect of taxol-containing liposomes in taxol resistant murine tumor model. Cancer Res. 53:1993;5877-5881.
82. Sharma A., Straubinger R.M., Ojima I., Bernacki R.J. Antitumor efficacy of taxane liposomes on a human ovarian tumor xenograft in nude athymic mice. J. Pharm. Sci. 84:1995;1400-1404.
83. Sharma U., Balasubramanian S.V., Straubinger R.M. Pharmaceutical and physical properties of paclitaxel (Taxol) complexes with cyclodextrins. J. Pharm. Sci. 84:1995;1223-1230.
84. Sharma D., Chelvi T.P., Kaur J., Chakravarti K., De T.K., Maitra A., Ralhan R. Novel taxol formulation: polyvinylpyrrolidine nanoparticle-encapsulated taxol for drug delivery in cancer. Oncol. Res. 8:1996;281-286.
85. Sharma A., Mayhew E., Bolcsak L., Cavanaugh C., Harmon P., Janoff A., Bernacki R.J. Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int. J. Cancer. 71:1997;103-107.
86. Smith J., Stock E., Orenberg E.K., Yu N.Y., Kanekal S., Brown D.M. Intratumoral chemotherapy with sustained-release drug delivery system inhibits growth of human pancreatic cancer xenografts. Anticancer Drugs. 6:1995;717-726.
87. Song D., Hsu L.-F., Au L.-S. Binding of taxol to plastic and glass containers and protein in vitro conditions. J. Pharm. Sci. 85:1996;29-31.
88. Sparreboom A., Asperen J.V., Mayer U., Schinkel A.H., Smit J.W., Meijer D.K.F., Borst P., Nooijen W.J., Beijen J.H., Tellinggen O.V. Limited oral bioavailability and epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. USA. 94:1997;2031-2035.
89. Stella V., Rajewski R.A. Their future in drug development and delivery. Pharm. Res. 14:1997;556-567.
90. Stemmer S., Cagnoni P.J., Shpall E.J., Bearman S.I., Matthes S., Dufton C., Day T., Taffs S., Hami L., Martinez C., Purdy M.H., Arron J., Jones R.B. High dose paclitaxel, cyclophosphamide, and cisplatin with autologous hematopoietic progenitor cell support: a phase I trial. J. Clin. Oncol. 5:1996;1463-1472.
91. Strerle A., Strobel G., Stierle D. Taxol and taxane production by Taxomyces andreanae, an endophytic fungus of Pacific yew. Science. 260:1993;214-215.
92. Suffness M. Taxol: from discovery to therapeutic use. Annu. Rep. Med. Chem. 28:1993;305-313.
93. Szeltli J. Medical applications of cyclodextrins. Med. Res. Rev. 14:1994;353-386.
94. Tamura T., Sasaki Y., Nishiwaki Y., Saijo N. Phase I study of paclitaxel by three hour infusion: hypotension just after infusion is one of the major dose limiting toxicities. Jpn. J. Cancer Res. 12:1995;1203-1209.
95. Tarr B., Yalkowsky S.H. New parenteral vehicles for administration of some poorly water soluble anti-cancer drugs. Bull. Parenter. Drug Assoc. 41:1987;31-33.
96. Tarr B., Sambandan T.G., Yalkowsky S.H. A new parenteral emulsion for administration of taxol. Pharm. Res. 4:1987;162-165.
97. Tolcher A., Cowan K.H., Solomon D., Ognibene F., Goldspiel B., Chang R., Noone M.H., Denicoff A.M., Barnes C.S., Gossard M.R., Fetsch P.A., Berg S.L., Balis F.M., Venzon D.J., O'Shaughnessy J.A. Phase I crossover study of paclitaxel with R verapamil in patients with metastatic breast cancer. J. Clin. Oncol. 14:1996;1173-1184.
98. Uchegbu I., McCarthy D., Schatzlein A., Florence A.T. Phase transitions in aqueous dispersions of the hexadecyl diglycerol ether (C16G2) nonionic surfactant, cholesterol and cholesteryl poly 24 oxyethylene ether: vesicles, tubules, discomes and micelles. STP Pharma Sciences. 6:1996;33-43.
99. Uekama, K., Hirayama, F., Irie, T., 1994. Application of cyclodextrins. In: de Boer, A.G.E. (Ed.), Drug Absorption Enhancement: Concepts, Possiblities, Limitations and Trends. Harwood Academic Publishers, Lanhgorne, PA, pp. 411-456.
100. Vander Velde D., Gorge G.I., Gruewald G.L., Gunn C.W., Mitscher L.A. Hydrophobic collapse of taxol and taxotere solution conformations in mixtures of water and organic solvent. J. Am. Chem. Soc. 115:1993;11650-11651.
101. Vyas D., Wong H., Crosswell A.R., Casazza A.M., Knipe J.O., Mamber S.W., Doyle T.W. Synthesis and antitumor evaluation of water soluble taxol phosphates. Bioorg. Med. Chem. Lett. 3:1993;1357-1360.
102. Walter K., Cahan M.A., Gur A., Tyler B., Hilton J., Colvin O.M., Burger P.C., Domb A., Brem H. Interstitial taxol delivered from biodegradable polymer implant against experimental brain tumors. Cancer Res. 54:1994;2207-2212.
103. Wani M., Taylore H.L., Wall M.E., Coggon P., McPhail A.T. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93:1971;2325-2337.
104. Waugh W., Trissel L.A., Stella V.J. Stability, compatibility, and plasticizer extraction of taxol (NSC 125973) injection diluted in infusion solutions and stored in various containers. Am. J. Hosp. Pharm. 48:1991;1520-1524.
105. Weiss R., Donehower R.C., Wiernik P.H. Hypersensitivity reactions from taxol. J. Clin. Oncol. 8:1990;1263-1268.
106. Wenk M., Fahr A., Reszka R., Seelig J. Paclitaxel partitioning into lipid bilayers. J. Pharm. Sci. 85:1996;228-231.
107. Whiterup K., Look S.A., Stasko M.W., Ghiorzi T.J., Muschik G.M., Cragg G.M. Taxus spp. needles containing amounts of taxol comparable to bark of Taxus brevifolia: analysis and isolation. J. Nat. Prod. 53:1990;1249-1255.
108. Winternitz C., Jackson J.K., Oktaba A.M., Burt M.H. Development of polymeric surgical paste formulation of taxol. Pharm. Res. 13:1996;368-375.
109. Woodcock D., Jefferson S., Linsenmayer M.E., Crowther P.J., Wlliams B., Bertanocello I. Reversal of multidrug resistance phentype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:1990;4199-4203.
110. Xu Q., Trissel L.A., Martinez J.F. Stability of paclitaxel in 5% dextrose injection or 0.9% sodium chloride injection at 4, 22, or 32 DGC. Am. J. Hosp. Pharm. 51:1994;3058-3060.
111. Yukimune Y., Tabata H., Higashi Y., Hara Y. Methyl jasmonate-induced overproduction of paclitaxel and baccatin II in Taxus cell suspension cultures. Nat. Biotechnol. 14:1996;1129-1132.
112. Zhang X., Jackson J.K., Burt H.M. Development of amphiphilic diblock copolymers as micellar carriers of taxol. Int. J. Pharm. 132:1996;195-206.
113. Zhang X., Jackson J.K., Wong W., Min W., Cruz T., Hunter W.L., Burt H.M. Development of biodegradable polymeric paste formulations for taxol: in vitro and in vivo study. Int. J. Pharm. 137:1996;199-208.
114. Zhao Z., Kingston D.G.I. Modified taxols, 6. Preparation of water-soluble prodrugs of taxol. J. Nat. Prod. 54:1991;1607-1611.